Search by Medical Condition

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Clinical Trials for Glomerulonephritis, IGA

• A Phase 1 Study of CLYM116 in Normal Healthy Volunteers
• A Study of Cizutamig in Patients With Immunoglobulin A Nephropathy
• To Evaluate the Effect and Safety of Telitacicept and Standard Treatment for 6months in IgA Nephropathy
• Tonsillectomy and Immunosuppression in Caucasian Patients With High-risk IgA-nephropathy
• Finerenone in Patients With IgA-nephropathy: Prospective Interventional Trial
• Study of BHV-1400 in IgA Nephropathy
• Clinical Study on the Efficacy and Safety of Telitacicept in the Treatment of Pediatric IgA Nephropathy or IgA Vasculitis Nephritis
• A Clinical Study to Evaluate the Effect of Food on the Pharmacokinetic Profiles of HRS-5965 Capsules in Healthy Subjects
• Nefecon and Ambrisentan in IgA Nephropathy
• Study of Ravulizumab in Pediatric Participants With Primary IgAN
• Monthly Dosing of Atacicept in IgAN
• A Trial of HRS-5965 Capsule in Primary IgA Nephropathy
• Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Iptacopan in Pediatric Patients With Primary IgAN
• Atacicept in Multiple Glomerular Diseases
• Evaluate the Efficacy and Safety of NTQ5082 Capsules in Patients With Primary IgA Nephropathy
• A Study to Learn About the Effects of Felzartamab Infusions on Adults With Immunoglobulin A Nephropathy (IgAN)
• Relative Bioavailability Study of HR19042 in Healthy Subjects
• Open-label Extension Study of Zigakibart in Adults With IgA Nephropathy.
• Study of CM313 in Subject With IgA Nephropathy
• A Study of SC0062 Capsule for the Treatment of IgA Nephropathy with Proteinuria
• Study to Evaluate the Impact of Iptacopan on Top of SOC on Biopsy Changes in Kidneys of Adult Patients With IgAN
• A Study of SGB-9768 in Patients with Complement-mediated Kidney Diseases
• Trial of the Impact of Sibeprenlimab on Immunoglobulin A Nephropathy Kidney Tissue
• Efficacy and Safety of Extended TARPEYO Treatment Beyond 9 Months in Adult Patients With Primary IgA Nephropathy
• Study to Evaluate the Efficacy and Safety of MY008211A in Subjects with Primary Immunoglobulin a Nephropathy (IgAN)
• Avacopan in Crescentic Immunoglobulin A Nephropathy (IgAN)
• Which of the Commonly Available and Approved Drugs in Addition to Standard of Care Can Significantly Improve the Slope of Estimated Glomerular Filtration Rate at Two Years When Compared to Standard of Care Alone in South-Asian Kidney Biopsy-prov
• A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Atacicept
• Phase II Study of Efficacy and Safety of HSK39297 Tablet in Treatment of Patients with Primary IgAN
• Efficacy and Safety of Telitacicept in IgAN
• A Study of the Effect and Safety of HS-10390 in the Treatment of Patients with Primary IgA Nephropathy
• Effect of Finerenone in IgA Nephropathy
• Evaluation of Efficacy of Povetacicept in Adults With Immunoglobulin A Nephropathy (IgAN)
• Efficacy and Safety of Probiotics Combined With Enteric-coated Budesonide Capsules in Patients With Primary IgA Nephropathy
• Study of WAL0921 in Patients With Glomerular Kidney Diseases
• Study of NM8074 in Patients With Immunoglobulin A Nephropathy (IgAN)
• A Phase 2 Study to Evaluate the Safety, PD, PK, and Clinical Activity of ADX-097 in Participants With IgAN, LN or C3G
• Therapeutic Effect of Hydroxychloroquine on Immunoglobulin A (IgA) Nephropathy Course QUIgAN Study
• Study of Ravulizumab in Immunoglobulin A Nephropathy (IgAN)
• Study of ARO-CFB in Adult Healthy Volunteers and Patients With Complement-Mediated Kidney Disease
• A Trial of HRS-5965 Tablets in Primary IgA Nephropathy
• A First in Human Study to Evaluate Safety, Tolerability, Pharmacology of HS-10390 in Healthy Subjects
• A Study to Investigate Safety and Effect of Sparsentan in Combination With SGLT2 Inhibition in Participants With IgAN
• A Study of BION-1301 in Adults With IgA Nephropathy
• Efficacy and Safety of SHR-2010 Injection in the Treatment of Primary IgA Nephropathy
• Randomized, Double-blind, Placebo-controlled, Crossover Study of Atrasentan in Subjects With IgA Nephropathy
• A Randomized, Controlled Clinical Study of Rituximab in Treatment of Primary IgA Nephropathy
• A Study of Telitacicept in Patients With Primary IgA Nephropathy
• A Study to Evaluate the Efficacy and Safety of RO7434656 in Participants With Primary Immunoglobulin A (IgA) Nephropathy at High Risk of Progression
• An Open-label Study of Povetacicept (ALPN-303) in Autoimmune Kidney Diseases.
• A Study to Evaluate the Efficacy and Safety of SC0062 in the Treatment of Chronic Kidney Disease
• Phase III Study of Telitacicept in Patients With IgA Nephropathy
• Efficacy and Safety in Chinese Patients With IgA Nephropathy Who Have Completed Study Nef-301
• Efficacy of Immunosuppressive Therapy for IgA Nephropathy With Stage 3 or 4 CKD
• A Study to Evaluate the Safety, Tolerability and Pharmacokinetics Pharmacodynamics of SHR-2010 by Intravenously/Subcutaneously in Healthy Subject
• Bortezomib for Treating Glomerular Diseases
• Phase 2/3 Open-Label Trial of Sibeprenlimab in the Treatment of Immunoglobulin A Nephropathy
• Visionary Study: Phase 3 Trial of Sibeprenlimab in Immunoglobulin A Nephropathy (IgAN)
• BCX9930 for the Treatment of C3G, IgAN, and PMN (RENEW)
• Safety and Efficacy of AT-1501 in Patients With IgA Nephropathy (IgAN)
• Study of ALXN2050 in Proliferative Lupus Nephritis (LN) and Immunoglobulin A Nephropathy (IgAN)
• Study of ARO-C3 in Adult Healthy Volunteers and Patients With Paroxysmal Nocturnal Hemoglobinuria and Complement-Mediated Renal Disease
• Clinical Trial to Assess Efficacy and Safety of the Human Anti-CD38 Antibody Felzartamab (MOR202) in IgA Nephropathy
• A Study to Evaluate the Efficacy and Safety of HR19042 Capsules in the Treatment of Primary IgA Nephropathy.
• Study of Sparsentan Treatment in Pediatrics With Proteinuric Glomerular Diseases
• A Study of Telitacicept for Injection (RC18) in Subjects With IgA Nephropathy
• A Trial of HR19042 Capsule in Healthy Chinese Subjects
• Steroids Therapy in IgA Nephropathy With Crescents
• Open-Label Extension Study of BION-1301 in IgA Nephropathy
• A Study of the Safety and Activity of Sparsentan for the Treatment of Incident Patients With Immunoglobulin A Nephropathy
• Multicentre Clinical Study to Evaluate the Effect of Personalized Therapy on Patients With Immunoglobulin A Nephropathy.
• Study of Efficacy and Safety of LNP023 in Primary IgA Nephropathy Patients
• Atrasentan in Patients With Proteinuric Glomerular Diseases
• Atrasentan in Patients With IgA Nephropathy
• Study of Ravulizumab in Proliferative Lupus Nephritis (LN) or Immunoglobulin A Nephropathy (IgAN)
• A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open Label Iptacopan/LNP023 in Participants With Primary IgA Nephropathy
• Efficacy and Safety in Patients With Primary IgA Nephropathy Who Have Completed Study Nef-301 (Nefigard-OLE)
• Rituximab and RASi in Patients With IgAN
• Safety and Efficacy Study of VIS649 for IgA Nephropathy
• Study of Safety and Efficacy of AVB-S6-500 in Patients With IgA Nephropathy
• Leflunomide Plus Low Dose Corticosteroid in Immunoglobulin A (IgA) Nephropathy With Renal Insufficiency
• A Study to Evaluate the Effectiveness and Safety of IONIS-FB-LRx, an Antisense Inhibitor of Complement Factor B, in Adult Participants With Primary IgA Nephropathy
• Safety and Tolerability of BION-1301 in Healthy Volunteers and Adults With IgA Nephropathy (IgAN)
• A Study of Cemdisiran in Adults With Immunoglobulin A Nephropathy (IgAN)
• A Study of the Effect and Safety of Sparsentan in the Treatment of Patients With IgA Nephropathy
• An Extended Access Program for Bardoxolone Methyl in Patients With CKD (EAGLE)
• Efficacy and Safety of Nefecon in Patients With Primary IgA (Immunoglobulin A) Nephropathy
• Effect of Immunosuppression in IgA Nephropathy
• Phase II Study Assessing Safety and Efficacy of APL-2 in Glomerulopathies
• Treatment Effects of Chinese Medicine (Yi-Qi-Qing-Jie Herbal Compound) Combined With Immunosuppression Therapies in IgA Nephropathy Patients With High-risk of ESRD
• Study of Safety and Efficacy of LNP023 in Patients With Kidney Disease Caused by Inflammation
• A Phase 2 Trial of the Safety and Efficacy of Bardoxolone Methyl in Patients With Rare Chronic Kidney Diseases - PHOENIX
• Treatment of IgA Nephropathy According to Renal Lesions
• Efficacy and Safety of a Combination of Mycophenolate Mofetil and Corticosteroid in Advanced IgA Nephropathy
• Efficacy and Safety of Atacicept in IgA Nephropathy
• Hydroxychloroquine Sulfate Alleviates Persistent Proteinuria in IgA Nephropathy
• Integrative Medicine of IgA Nephropathy
• Validity and Security of Reh-acteoside Therapy for Patients of IgA Nephropathy
• Trial of Plasma Exchange for Severe Crescentic IgA Nephropathy
• Rituximab in Recurrent IgA Nephropathy
• Prevention in Recipients With Primary IgA Nephropathy of Recurrence After Kidney Transplantation: ATG-F Versus Basiliximab as Induction Immunosuppressive Treatment
• Open Label Study of Fostamatinib in the Treatment of IgA Nephropathy
• Open-Label Study to Evaluate Safety and Efficacy of CCX168 in Subjects With Immunoglobulin A Nephropathy on Stable RAAS Blockade
• Acthar on Proteinuria in IgA Nephropathy Patients
• Hydroxychloroquine Sulfate for Reduction of Proteinuria in Patients With IgA Nephropathy: a Self- Controlled Study
• Pilot Study of ACTH in the Treatment of Immunoglobulin A (IgA) Nephropathy at High Risk of Progression
• Efficacy and Safety of Losartan in Children With Ig A Nephropathy
• Efficacy and Safety of Abelmoschus Manihot for IgA Nephropathy
• Treatment of IgAN With Multi-glycoside of Tripterygium Wilfordii HOOK. f.
• A Controlled Study of Steroids Therapy for Patients of IgA Nephropathy With Active Pathological Changes.
• Safety and Efficacy Study of Fostamatinib to Treat Immunoglobin A (IgA) Nephropathy
• BRIGHT-SC: Blisibimod Response in IgA Nephropathy Following At-Home Treatment by Subcutaneous Administration
• BRILLIANT-SC: A Study of the Efficacy and Safety of Blisibimod Administration in Subjects With IgA Nephropathy
• Study of Standardized Treatment of Integrative Medicine With the Severe IgA Nephropath
• The Effects of Mycophenolate Mofetil (MMF) on Renal Outcomes in Advanced Immunoglobulin A (IgA) Nephropathy Patients
• Treatment of Prednisone Plus Cyclophosphamide in Patients With Advanced-stage IgA Nephropathy
• The Effect of Nefecon® in Patients With Primary IgA Nephropathy at Risk of Developing End-stage Renal Disease
• Therapeutic Evaluation of Steroids in IgA Nephropathy Global Study (TESTING Low Dose Study)
• The Effectiveness of Enough Steroids as Inducement Therapy in Minimal Change Disease-like IgA Nephropathy
• Steroids and Azathioprine in Advanced IgAN
• An Multi-site Prospective Study to Assess the Efficacy and Safety of MMF in the Treatment of Proliferative IgA Nephropathy(IgAN)
• Additive Renoprotective Effects of Oral Calcitriol in IgA Nephropathy Patients Taking Renin-Angiotensin System Blockers
• Treatment of Early Immunoglobulin A Nephropathy by Angiotensin Converting Enzyme Inhibitor - A Randomized Controlled Trial
• A Study to Evaluate the Efficacy and Safety of Tacrolimus in Korean Nephropathy Patients
• A Prospective Study of the Kidney Protective Effect of Aliskiren in Hypertensive Patients With IgA Nephropathy
• Aldosterone Breakthrough During Diovan, Tekturna, and Combination Therapy in Patients With Proteinuric Kidney Disease
• Inhibitors of Angiotensin II in Proteinuric Mesangioproliferative Glomerulonephritis
• Pilot Study of Velcade® in IgA Nephropathy
• Aliskiren for Proteinuric IgAN Despite Angiotensin Blockade
• Prospective Study of TW in Treatment of IgAN With Asymptomatic Abnormal Urinalysis
• Aliskiren for Immunoglobulin A (IgA) Nephropathy
• Mycophenolate Mofetil for IgA Nephropathy
• Calcitriol in the Treatment of Immunoglobulin A Nephropathy
• A Controlled Study of Uric Acid on the Progression of IgA Nephropathy
• Oral Treatment With PL-56 in Patients With IgA Nephropathy - an Explorative Study
• "Steroids and Azathioprine Versus Steroids Alone in IgAN"
• Mycophenolate Mofetil (MMF) in Patients With IgA Nephropathy (IgAN)
• Paricalcitol for the Treatment of Immunoglobulin A Nephropathy
• Supportive Versus Immunosuppressive Therapy for the Treatment Of Progressive IgA Nephropathy
• Efficacy and Safety of Omega-3 Fatty Acids(Omacor®) for the Treatment of Immunoglobulin A Nephropathy
• Rituximab in Progressive Immunoglobulin A (IgA) Nephropathy
• Effects of Mycophenolate Mofetil (MMF) On Anti-HLA (Human Leukocyte Antigen)Antibody Levels In Patients Awaiting Cadaveric Renal Transplant.
• Effects of Rituximab and Mycophenolate Mofetil (MMF) on Highly Sensitized Patients Awaiting Renal Transplant
• A Study of the Antioxidant Probucol Combined With Valsartan in Patients With IgA Nephropathy
• Sirolimus Therapy for Poor Prognosis Immunoglobulin A Nephropathy
• ACEi/ARB Alone Versus ACEi/ARB Plus Steroids in the Treatment of Primary IgA Nephropathy, a RCT
• Inhibition of the Renin Angiotensin System Plus Corticosteroids for the Treatment of Proteinuria in IGA Nephropathy
• Calcitriol in the Treatment of Immunoglobulin A (IgA) Nephropathy
• Mycophenolate Mofetil (MMF) in Patients With IgA Nephropathy
• Mycophenolate Mofetil Versus Intravenous Cyclophosphamide Pulses in the Treatment of Crescentic IgA Nephropathy
• Pilot Study of Enalapril and Renal Function in Patients With IgA Nephropathy
• Alternate Day Prednisone or Daily Fish Oil Supplements in Patients With Immunoglobulin A Nephropathy